IP Library › Patent Application 17937994
Patent Application
App. No. 17/937,994

CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/937,994
Abstract

The present disclosures are directed to chlorinated tetralin compounds and pharmaceutical compositions.

Claims (20)

1 - 16 . (canceled)

17 . A pharmaceutical composition comprising a compound of Formula IC which is

or a pharmaceutically acceptable salt thereof.

18 . The pharmaceutical composition according to claim 17 , wherein the compound of Formula IC is present in an amount of about 1 μg to about 100 μg.

19 . The pharmaceutical composition according to claim 17 , wherein the compound of Formula IC is present in an amount of about 1 μg to about 50 μg.

20 . The pharmaceutical composition according to claim 17 , wherein the compound of Formula IC is present in an amount of about 1 μg to about 40 μg.

21 . The pharmaceutical composition according to claim 17 , wherein the compound of Formula IC is present in an amount of about 5 μg to about 50 μg.

22 . The pharmaceutical composition according to claim 17 , wherein the compound of Formula IC is present in an amount of about 10 μg to about 50 μg.

23 . The pharmaceutical composition according to claim 17 , wherein the compound of Formula IC is present in an amount of about 15 μg to about 40 μg.

24 . The pharmaceutical composition according to claim 17 , further comprising a gamma-secretase inhibitor selected from the group consisting of nirogacestat or a pharmaceutically acceptable salt thereof, crenigacestat or a pharmaceutically acceptable salt thereof, AL101 or a pharmaceutically acceptable salt thereof, AL102 or a pharmaceutically acceptable salt thereof, semagacestat or a pharmaceutically acceptable salt thereof, avagacestat or a pharmaceutically acceptable salt thereof, and ianabecestat or a pharmaceutically acceptable salt thereof.

25 . The pharmaceutical composition according to claim 17 , further comprising nirogacestat or a pharmaceutically acceptable salt thereof.

26 . The pharmaceutical composition according to claim 17 , wherein the pharmaceutical composition is for oral administration.

27 . A pharmaceutical composition comprising a compound of Formula IC which is

or a pharmaceutically acceptable salt thereof and nirogacestat or a pharmaceutically acceptable salt thereof.

28 . The pharmaceutical composition according to claim 27 , wherein the compound of Formula IC is present in an amount of about 1 μg to about 100 μg.

29 . The pharmaceutical composition according to claim 27 , wherein the compound of Formula IC is present in an amount of about 1 μg to about 50 μg.

30 . The pharmaceutical composition according to claim 27 , wherein the compound of Formula IC is present in an amount of about 1 μg to about 40 μg.

31 . The pharmaceutical composition according to claim 27 , wherein the compound of Formula IC is present in an amount of about 5 μg to about 50 μg.

32 . The pharmaceutical composition according to claim 27 , wherein the compound of Formula IC is present in an amount of about 10 μg to about 50 μg.

33 . The pharmaceutical composition according to claim 27 , wherein the compound of Formula IC is present in an amount of about 15 μg to about 40 μg.